Aetna Auditory Processing Disorder Coverage Update

Coverage Determinations for APD

Overall coverage stance

Covered when ALL of the following are met

APD coverage stance: Aetna considers any diagnostic tests or treatments for management of APD experimental and investigational due to insufficient scientific evidence to support diagnostic validity and treatment effectiveness.

Policy statement: APD testing and treatments are experimental/investigational.

Coverage considerations and decision nodes

Interpret diagnostic testing and coverage decisions in the context of the following considerations:

Diagnostic uncertainty and comorbidity: APD diagnosis requires differentiation from ADHD, ASD, dyslexia, intellectual impairment, and specific language impairment; when another disorder better explains the presenting problems, that diagnosis takes precedence.

Reflects guidance that cognitive/language disorders may trump APD diagnosis and that APD boundaries are unclear.

Test selection: Use validated, well-normalized tests relevant to the reported problems; consider including non-speech stimuli and select a smaller battery of well-validated measures (for example, speech-in-noise tests and standardized questionnaires) rather than large unvalidated batteries.

BSA recommends at least one test use non-speech stimuli; guidance encourages well-validated, relevant test selection.

Interpretation standards: Specify the diagnostic failure criteria used for the battery, recognizing that definitions vary (examples: AAA — 2 tests ≥2 SDs below mean; ASHA — performance ≥2 SDs below mean on ≥2 tests or ≥3 SDs below mean on 1 test with significant functional difficulty).

No universally accepted failure definition; document which guideline/cut-offs were applied.

Electrophysiology: Electrophysiologic measures (eg, FFR, ABR components, cortical potentials) may be useful adjuncts; some modalities (eg, FFR) have more supporting literature, but variability in diagnostic criteria and testing conditions limits generalizability and standardized norms are lacking.

Evidence limited and heterogeneous; electrophysiologic results may not be applicable across differing diagnostic criteria.

Interventions and devices promoted for APD (including FM systems, computer-based auditory training, auditory integration, and many formal auditory training programs) have limited or low-quality APD-specific evidence; coverage decisions should require documentation of expected benefit and prior conservative, evidence-based management when appropriate.

Interventions lack robust randomized controlled trial evidence for APD-specific efficacy.

Aetna considers any diagnostic tests or treatments for auditory processing disorder (APD) to be experimental and investigational because the scientific evidence does not adequately support diagnostic validity or treatment effectiveness. This policy therefore excludes claims for APD-specific testing or therapeutic interventions unless reliable evidence demonstrates medical benefit.

The policy rationale cites limited evidence that APD is a distinct pathophysiologic entity, no consensus on diagnostic criteria or validated instruments to distinguish APD from other disorders affecting listening/spoken language, and a lack of well-designed clinical trials proving intervention effectiveness.

Interventions and devices commonly promoted for APD — including personal FM systems, computer-based auditory training programs, and other auditory training approaches — have limited or low-quality evidence specific to APD. Systematic reviews and evidence summaries have not established consistent, robust treatment effects for these modalities in persons diagnosed with APD.

Reviews identified few high-quality studies and classified much of the available literature as low-level evidence (case studies, expert opinion). As a result, these device- and program-based interventions are not supported as proven APD treatments in this policy.

Available adult studies of behavioral auditory processing testing have primarily enrolled persons aged 18 to 64 years without peripheral hearing loss. These studies are heterogeneous in target populations and test selection, and they provide limited normative benchmarks for age groups within adulthood.

Because much of the literature focuses on adults without hearing loss and uses diverse methods, the applicability of those results to children, older adults, or individuals with coexisting hearing impairment is limited and should be interpreted cautiously.

Specific interventions such as auditory integration training and many formal auditory training programs lack sufficient evidence of effectiveness for APD. Systematic reviews and evidence appraisals have found weak or inconsistent support for benefit and noted that improvements are often limited to trained auditory functions with little demonstrated transfer to spoken or written language outcomes.

Because the evidence base is small and methodologically limited, these interventions are not supported as medically necessary treatments for APD under this policy.

Using behavioral or electrophysiologic tests in isolation — particularly measures that are not standardized, well-normalized, or validated for APD diagnosis — may be insufficient to establish the diagnosis or to justify device-based interventions. The literature documents multiple different diagnostic criteria sets and inconsistent test reliability.

Providers should be aware that absence of standardized norms and agreed failure criteria for many commonly used tests increases the risk that test results alone will not support medical necessity or coverage decisions.

Procedure and Diagnosis Codes

Codes listed in policymixed

92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual.
92508	Treatment of speech, language, voice, communication, and/or auditory processing disorder; group, two or more individuals.
92521	Evaluation of speech fluency (eg, stuttering, cluttering).
92522	Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria).
92523	Evaluation of speech sound production; with evaluation of language comprehension and expression (eg, receptive and expressive language).
92524	Behavioral and qualitative analysis of voice and resonance.
92551-92588	Audiological function tests with medical diagnostic evaluation.
92620	Evaluation of central auditory function, with report; initial 60 minutes.
92621	Evaluation of central auditory function, each additional 15 minutes.
S9128	Speech therapy, in the home, per diem.

1–10 of 13

1/2

Provider Responsibilities, Authorization, and Documentation

Prior Authorization

Prior Authorization Recommended — Experimental/Investigational Risk

Any diagnostic tests or treatments for auditory processing disorder (APD) are considered experimental/investigational by Aetna when there is insufficient scientific evidence to support their validity or effectiveness. Prior authorization is recommended for proposed testing or interventions to confirm coverage and allow clinical review.

Tests/treatments lacking validated diagnostic criteria or proven clinical benefit may be denied as experimental/investigational.

Denial Risk

Justify Tests/Interventions with Evidence

When requesting authorization, providers should justify proposed tests and interventions with current peer‑reviewed evidence supporting their validity and clinical utility. Requests that rely on nonstandard or unvalidated testing methods (including proprietary or inconsistent test batteries) may be denied as not medically necessary.

Include literature citations or guideline support for chosen diagnostic tests or treatments.

Background and Context

Auditory processing disorder (APD), also referred to as central auditory processing disorder, is a proposed condition characterized by impaired processing of auditory information despite normal peripheral hearing. The diagnosis is controversial: consensus on diagnostic criteria is lacking and there is no established diagnostic gold standard.

APD frequently co-occurs with other conditions that affect listening and language function (for example, attention-deficit/hyperactivity disorder, language and learning disorders). Because of overlapping features and limited test reliability, many experts and reviews conclude that APD may not represent a distinct clinical entity and that interdisciplinary evaluation is required to differentiate APD from other neurodevelopmental disorders.

Definitions and Key Terms

inv-22: Auditory Processing Disorder (APD) definition

TermAuditory Processing Disorder (APD)

DefinitionA purported disorder interfering with the input and integration of verbal information despite normal peripheral hearing; diagnosis remains controversial with no established gold standard.

Key clinical pointsFrequently co-occurs with ADHD, language, learning, and speech-language impairments; prevalence estimates vary and causes are unclear.

inv-23: Experimental and investigational (for APD) definition

TermExperimental and investigational (for APD)

DefinitionAetna considers any diagnostic tests or treatments for management of APD experimental and investigational due to insufficient scientific evidence supporting diagnostic validity and treatment effectiveness.